ZhongMei Capital

Overview

ZhongMei Capital is a private investment firm specializing in biopharmaceutical investments with US-China market synergies. The firm focuses on pre-clinical stage biopharmaceutical companies that present cross-border collaboration opportunities, aiming to bridge capital, technology, scientists, and cultures between the two countries. ZhongMei Capital seeks to identify and invest in assets that address underserved disease states, partnering with entrepreneurs to unlock hidden value and create substantial returns. The firm's core business model centers on finding undervalued assets in China with potential for development in the United States, collaborating closely with US-based investors, contract research organizations, and clinical pharmaceutical companies to enhance the development prospects of its portfolio companies. Additionally, ZhongMei Capital invests in specific US-based start-ups developing assets of interest to large domestic Chinese pharmaceutical companies, facilitating partnerships and expansion into the Chinese market. ZhongMei Capital is committed to serving as a bridge linking capital, technology, scientists, and cultures, fostering global partnerships and mutual understanding to achieve both financial success and positive societal impact.

Investment Focus

• Pre-clinical stage biopharmaceutical companies
• Cross-border collaboration opportunities
• Assets addressing underserved disease states
• Entrepreneurs seeking long-term partnerships
• Companies with potential for development in the United States
• US-based start-ups with assets of interest to Chinese pharmaceutical companies

Portfolio Companies